|
Luo, F R; Wyrick, S D; Chaney, S G (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19-28
|
|
Luo, F R; Wyrick, S D; Chaney, S G (1999) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 13:159-69
|
|
Luo, F R; Wyrick, S D; Chaney, S G (1999) Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44:29-38
|
|
Ding, H; Goldberg, M M; Raymer, J H et al. (1999) Determination of platinum in rat dorsal root ganglion using ICP-MS. Biol Trace Elem Res 67:1-11
|
|
Luo, F R; Yen, T Y; Wyrick, S D et al. (1999) High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B Biomed Sci Appl 724:345-56
|
|
Holmes, J; Stanko, J; Varchenko, M et al. (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46:342-51
|
|
Chaney, S G; Sancar, A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88:1346-60
|
|
Thompson, D C; Wyrick, S D; Holbrook, D J et al. (1995) HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol 50:1413-9
|
|
Thompson, D C; Wyrick, S D; Holbrook, D J et al. (1995) Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma. Cancer Res 55:2837-46
|
|
Sakata, M; Chaney, S G; Spriggs, D R (1995) Possible correlation between ormaplatin biotransformations and neurotoxicity. Oncol Res 7:67-71
|
Showing the most recent 10 out of 12 publications
